Business Wire

Gallagher Re Joins ABIR and EY as 2023 Bermuda Risk Summit Headline Sponsors

3.2.2023 18:17:00 EET | Business Wire | Press release

Share

The Bermuda Business Development Agency (BDA) is pleased to announce that Gallagher Re has joined the Association of Bermuda Insurers and Reinsurers (ABIR) and EY as headline sponsors of the second annual Bermuda Risk Summit.

Adam Schwebach, Executive Vice President, Gallagher Re, said, “Gallagher Re is proud to support the second Bermuda Risk Summit, an annual event that showcases the breadth and versatility of Bermuda’s globally significant risk market. This event serves as a timely opportunity to connect with industry leaders ahead of midyear renewals and we applaud the BDA for their efforts in making the Bermuda Risk Summit a success.”

David Hart, BDA CEO, said, “We are just so excited to welcome Gallagher Re as our third and final headline sponsor, along with ABIR and EY. The theme of the 2023 Bermuda Risk Summit, being held from March 6-8, 2023, at the Hamilton Princess & Beach Club is ‘Innovation, Sustainability and Collaboration. We anticipate an even stronger attendance level than last year, as this event is just placed perfectly in front of an extremely important June 1 renewal season.”

Guests should act before midnight on Monday, February 6 to secure special hotel room rates starting at $359 (plus tax). From February 7, hotel room rates will increase significantly, or may be sold out, due to limited availability. To book your room please call 1-441-295-3000 or the Global Reservations Centre on 1-800-441-1414. Alternatively, click here to reserve your room online. Please use the booking code: ‘Bermuda Risk’ to take advantage of the preferred rate.

The Bermuda Risk Summit will begin with a keynote conversation with Bermuda’s Premier and BDA CEO David Hart, while Sophie Roberts, Head of The Insurer TV will moderate a group CEO panel made up of Peter Bell, CEO, Everest Re, Stephen Catlin, CEO, Convex, Chris Schaper, CEO, AIG, and Megan Thomas, CEO, Hamilton Re.

The BDA is also pleased to announce that Bermuda Brokers, Florida Insurance Council, KPMG, Meenan P.A., MS Reinsurance and Rein4ce have come on board as supporting sponsors. Goslings will be our spirits partner.

They join diamond sponsor Hyperexponential, gold sponsor SS&C, silver sponsors AM Best and Kirkland & Ellis, WIFI sponsor Demotech, supporting sponsor Aon, and our official media partner, The Insurer.

Other sponsorship opportunities are still available. Please e-mail bermudarisk@bda.bm if you wish to participate.

Some of the speakers confirmed to date include John Huff, CEO, ABIR, who will moderate a global capacity shortfall panel with Chris Bonard, CEO, ED Broking (Bermuda) Limited, Lara Mowrey, Global Head of Distribution, Guy Carpenter, Jim Fiore, Executive Managing Director, Chief Strategy Officer, Capital Advisory, Aon, and Ben Radford, Head of Gallagher Re, Bermuda.

Susanne K Murphy, Insurance Regulatory Consultant, Meenan P.A. will moderate a market perspectives from Florida’s C-Suite panel featuring Tom Gallagher, COO, People’s Trust Insurance Company, Melissa Burt DeVriese, President, Security First Insurance, Jennifer Montero, Chief Financial Officer, Florida Citizens Property Insurance Corporation and Cecil Pearce, President, Florida Insurance Council.

Suzanne Williams Charles, Director of Policy and Regulation, ABIR will moderate a panel of international regulators featuring Chlora Lindley-Myers, President, National Association of Insurance Commissioners and Gerald Gakundi, Director, Supervision (Insurance), Bermuda Monetary Authority (BMA) and Andrew Dyer, Head of London Markets, Bank of England.

Joseph Petrelli, President, Demotech and Todd Kozikowski, President, 44North, LLC, will present their findings on Florida’s disparate litigation levels.

Curtis Dickinson, Executive Adviser, Bermuda International Long-Term Insurers and Reinsurers (BILTIR) will moderate an updates from the life sector panel featuring Mark Yu, Head of Enterprise Capital Strategy, New England Asset Management, James Claxton, Associate Partner, EY, Martin Maringi, Deputy Director, Supervision (Insurance), BMA and Michelle Moloney, EVP Chief Risk Officer, Pacific Life Reinsurance.

Christian Dunleavy, Group Chief Underwriting Officer, Aspen, Chris Hayward, Chief Underwriting Officer, MS Amlin Reinsurance, Seamus Fearnon-EVP, CRT & European Markets, Arch Capital Group Ltd and Kostya Zolotusky, CEO, Itasca Re will explore the growing significance of specialty lines.

Kerr Kennedy, Associate Partner, EY, will moderate the future of cyber reinsurance panel with Yosha Delong, Global Head of Cyber, Mosaic Insurance, Noel Pearman, SVP, Cyber Product Line Leader, AXA XL, Sebastien Plummer, Cyber Specialist Broker, Gallagher Re, and Edouard Von Heberstein, CEO Spectra.

Edward Mishambi, SVP and Chief Risk Officer-Europe, Renaissance Re who will moderate a panel entitled global financing conditions – a rating agency discussion that features Peter Giacone, Global Head of Insurance, KBRA, Stefan Holzberger, Chief Rating Officer, AM Best, Brian Schneider, Senior Director, Global Analytical Co-Head, Fitch, and Joseph Petrelli.

A panel discussing investor’s experiences of Bermuda featuring Scott Frederick, Managing Partner, Sands Capital Ventures, Adrian Jones, Managing Director, Re/Insurance and Partner, HSCM Ventures, and Armin Rothauser, Senior Partner, Castlelake Investments will be moderated by Stephen Weinstein, past BDA Chair.

Saadia Savory, Vice President, Excess Casualty, Aspen, and Shannon Totten, SVP, Casualty Insurance Practice Leader Bermuda, Sompo International, will discuss Bermuda’s vibrant casualty lines of business.

And finally, Gero Michel, Group CRO, AIG Re will discuss the future of risk with Tom Johansmeyer, SVP, Head of PCS, Verisk, Susan Pateras, Deputy Chair, BDA, and Andrew Smith-Chief Risk & Sustainability Officer, Conduit Re.

The full agenda is available here.

The immediate economic impact of our 2022 event, which had a total of 350 delegates (80 from overseas), including lodging, transportation, food and beverage, retail and recreation was estimated at over one million dollars, and supported around 200 jobs.

CONNECTING BUSINESS

The BDA encourages direct investment and helps companies start up, re-locate, or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Stuart Roberts, Director of Communications & PR
stuart@bda.bm | +1 441 292 7774

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release

PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release

Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release

Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye